Background: Baseline predictors of myocardial recovery after cardiac resynchroniza-
| INTRODUC TI ON
Heart failure (HF) with reduced left ventricular ejection fraction (LVEF) is a heterogeneous condition where myocardial recovery is infrequently observed (Mann, Barger, & Burkhoff, 2012; Wilcox et al., 2015) . A common metric for treatment success is LVEF improvement. Those with recovered LVEF are not well described, but appear to have more favorable outcomes compared to those with persistently reduced LVEF (Basuray et al., 2014; Yancy et al., 2013) .
These observations extend to cardiac resynchronization therapy (CRT) recipients, which are recommended for select individuals (Ruwald et al., 2014) .
Reported predictors for CRT super-response include nonischemic cardiomyopathy (NICM) and left bundle branch block (LBBB; Hsu et al., 2012) . The strictest definition of super-response is LVEF ≥50%, or myocardial recovery (Steffel & Ruschitzka, 2014) . To date, no studies have reported predictors of myocardial recovery in those with LBBB-associated idiopathic NICM. Theoretically, identifying clinical predictors may offer insight into optimizing CRT response.
In addition, myocardial recovery after CRT is one criterion in a proposed definition of LBBB-induced cardiomyopathy (Vaillant et al., 2013) .
The NEw-Onset LBBB-Associated Idiopathic Nonischemic
CardiomyopaTHy (NEOLITH) II study was conducted in CRT recipients with LBBB at the time of initial diagnosis of idiopathic NICM (Wang, Li, et al., 2018) . This substudy sought to address two hypotheses: (a) baseline characteristics would differ between those who did and did not exhibit myocardial recovery and (b) clinical outcomes would differ between those who did and did not exhibit myocardial recovery.
| ME THODS

| Study population and design
The NEOLITH II study was a retrospective cohort study conducted at the University of Pittsburgh Medical Center (Wang, Li, et al., 2018) . Subjects implanted with CRT devices between January 1998 and April 2016 was identified from a prospectively maintained database. The derivation of the original study cohort, definition of idiopathic NICM, and exclusion criteria have been previously reported (Wang, Li, et al., 2018) . This substudy consisted of the 105 subjects with LVEF assessment after CRT.
All subjects had LBBB at the time of initial diagnosis of NICM.
LBBB was determined by 12-lead electrocardiograms recorded at 25 mm/s with automated QRS duration confirmed by a board-certified cardiologist. The definition of LBBB used was that recommended by the American Heart Association, the American College of Cardiology Foundation, and the Heart Rhythm Society (Surawicz, Childers, Deal, & Gettes, 2009) . The presence of "strict" LBBB was assessed, but not used in analyses (Strauss, Selvester, & Wagner, 2011 ).
CRT implants were performed using a transvenous approach by electrophysiologists at the University of Pittsburgh Medical Center.
Lateral and posterior coronary sinus branches were primary targets.
Epicardial left ventricular (LV) leads were surgically placed when transvenous approaches were unsuccessful. The final lead position was determined by chest radiography using a standardized technique (Wilton et al., 2008) . Device programming was at the discretion of the treating physicians. The study was approved by the University of Pittsburgh Institutional Review Board. Informed consent was not required because of the retrospective nature of the study.
| Covariates and outcomes
Clinical information documented as part of routine clinical care was collected from electronic medical records. Baseline demographics, laboratory values, medical history, echocardiographic data, and medications were those measured on the morning of CRT implantation or closest outpatient visit prior to CRT implant. Race/ ethnicity was self-described. Alcohol consumption was categorized based on a previously validated scale (Kloner & Rezkalla, 2007) .
Angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II receptor blocker (ARB) use were merged into one variable. Percent target dose achieved for ACEIs/ARBs, beta-blockers, and aldosterone antagonists were calculated as previously described (Wang et al., 2016) . The time from diagnosis to CRT was measured from the date of the first imaging modality to reveal an LVEF ≤35% to the date of CRT implant. ΔQRS was the change in QRS duration during the CRT implant visit, defined as the difference between the CRT-paced and the LBBB QRS durations.
LVEF was determined from transthoracic echocardiography using biplane Simpson's method and Teichholz's formula and confirmed by board-certified cardiologists. When reported as a range, the midpoint was assigned (i.e., 32.5 for LVEF reported as 30%-35%). Additional parameters recorded included LV end-diastolic dimension, LV end-systolic dimension, and left atrial dimensions.
These were indexed to body surface area, using the Mosteller formula (Lang et al., 2015; Mosteller, 1987) .
The primary outcome was myocardial recovery after CRT. It was defined as a "post-CRT LVEF" measurement of ≥50% on the most recent transthoracic echocardiogram. This threshold represents normalization of LVEF (Yancy et al., 2013) . The LVEF measurement after optimal GDMT and immediately prior to CRT was designated the "post-GMDT LVEF". For descriptive purposes, we calculated the difference between post-CRT LVEF and post-GDMT LVEF, or ΔLVEF CRT . A threshold of ΔLVEF CRT ≥ 15% approximates a previously reported metric for super-response (Hsu et al., 2012) .
The primary clinical outcome was a composite of adverse clinical events that included HF hospitalization, appropriate implantable cardioverter-defibrillator (ICD) shock, appropriate anti-tachycardia pacing (ATP) therapy, ventricular assist device implantation, heart transplantation, and death. The secondary clinical outcome was allcause mortality. Time to clinical outcome events was measured from the date of CRT implantation. 
| Statistical methods
Obstructive sleep apnea 7 (6.7) 3 (6.1) 4 (7.1) 0.83 range (IQR) with comparisons using Wilcoxon-Mann-Whitney tests.
Logistic regression was used to estimate the odds ratios (ORs) between subject characteristics and post-CRT LVEF ≥50% vs. <50%.
Time-to-event outcomes were summarized using Kaplan-Meier survival curves. Cox regression was used to estimate the hazard ratios (HRs) between groups for adverse clinical events and all-cause mortality.
Multivariate analyses were performed, adjusting sequentially for potential confounders. We did not assign a value for "significance" for p values, as suggested by the American Statistical Association, but recognize the traditional threshold of p < 0.05 (Wasserstein & Lazar, 2016) . Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary NC).
| RE SULTS
In the NEOLITH II study, 105 of 123 (85%) subjects had post-CRT LVEF measurements and were included in the present study (Wang, Li, et al., 2018) . The baseline characteristics of the final cohort and by post-CRT LVEF group are presented in Table 1 . Characteristics of the 18 excluded subjects included mean age 71.6 ± 12.5 years, 9 (50%) male, 14 (78%) with history of hypertension, 14 (78%) with cardiac catheterization, and 13 (72%) with time from diagnosis to CRT >9 months.
All subjects were in sinus rhythm at the time of CRT implant.
Myocardial recovery, or post-CRT LVEF ≥50%, was observed in 56 (53%) subjects. LBBB with QRS duration ≥150 ms prior to CRT Table 2 . ACEIs/ARBs included lisinopril (n = 56), enalapril (n = 7), quinapril (n = 5), ramipril (n = 1), captopril (n = 1), benazepril (n = 1), moexipril (n = 1), losartan (n = 12), valsartan (n = 8), irbesartan (n = 4), candesartan (n = 1), and olmesartan (n = 1). Beta-blockers included carvedilol (n = 84), carvedilol extended release (n = 3), metoprolol succinate (n = 6), metoprolol tartate (n = 6), atenolol (n = 1), and nadolol (n = 1). Reasons for not taking ACEI/ARB included low blood pressure (n = 3), renal dysfunction (n = 2), and unspecified (n = 2). Reasons for not taking beta-blockers included symptoms concerning for medications side effects (n = 3), low blood pressure (n = 1), and unspecified (n = 1).
Aldosterone antagonists were all spironolactone (n = 21). No subjects were taking angiotensin receptor-neprilysin inhibitors or ivabradine.
CRT characteristics are listed in Table 2 . Transvenous LV lead placement was achieved in 102 (97.1%) subjects; 3 (2.9%) received epicardial leads. The distribution of transvenous leads was similar between groups and consisted of 23 quadripolar, 64 bipolar, and 15 unipolar.
| Associations of subject characteristics with myocardial recovery after CRT
Univariable logistic regression analyses are listed on Table 3 .
Negative associations were observed between post-CRT LVEF ≥50% Multivariable logistic regression analyses are listed in Table 4 .
Multicollinearity was apparent when hypertension and diabetes were analyzed in the same model (model 1). Therefore, hypertension and diabetes were analyzed in separate models, models 2 and 3, respectively. Our final model included hypertension, heart rate, and serum
BUN (model 2). Associations observed in univariable analyses per-
sisted in the final multivariable model.
| Clinical outcomes
The Table 5 .
The post-CRT LVEF ≥50% group had similar risk for all-cause mortality when compared to the post-CRT LVEF <50% group (HR, 0.55; 95% CI, 0.16-1.82; p = 0.33) (Figure 3 ). The estimated 5-year mortality was 4.0% in the LVEF ≥50% group and 7.4% in the LVEF <50% group.
| D ISCUSS I ON
This analysis from the NEOLITH II study is the first to assess predictors of myocardial recovery, or post-CRT LVEF ≥50%, after CRT in subjects with LBBB confirmed at the time of initial diagnosis of idiopathic NICM. Over half in our study experienced normalization of LVEF. Hypertension, higher heart rate, and higher serum BUN were negatively associated with myocardial recovery. LVEF normalization after CRT was associated with fewer adverse clinical events. These findings may lend insight into pathophysiologic processes underlying LBBB-associated NICM, provide outcome data to assist in directing patient care, and identify areas of future investigation.
There is increasing evidence that LBBB-induced cardiomyopathy is a distinct clinical entity. A proposed definition included normalization of LVEF after CRT as a criterion (Vaillant et al, 2013) .
Our results suggest that approximately half who met the inclusion and exclusion criteria of the NEOLITH II study have LBBB-induced cardiomyopathy. Subjects who achieved myocardial recovery had significantly fewer adverse clinical events than those who did not.
This population has limited response to GDMT alone and has high postdischarge event rates after HF hospitalization (Sze et al., 2018; Wang et al., 2008 Wang et al., , 2016 . Not only does CRT appear to be critical in the optimal treatment of these patients, but earlier implant may also confer additional beneficial (Wang, Li, et al., 2018) . Time from diagnosis to CRT was not significantly associated with myocardial recovery in the present analysis, but this may be related to our modest sample size.
The favorable results we observed provide additional evidence that switching from CRT-defibrillators to CRT pacemakers may be reasonable in those without prior appropriate ICD therapies.
Thus, ICD leads with IS-1 connectors are preferred in current generation CRT-defibrillator systems (Sticherling & Burri, 2012 given the high rate of LBBB and CRT in the study population (Køber et al., 2016) . In fact, blanket use of ICDs in NICM patients who receive CRT is questionable (Golwala, Bajaj, Arora, & Arora, 2017) . Larger LV end-diastolic dimension prior to CRT implant and LV midwall fibrosis may be useful risk stratification tools to recommend CRT-defibrillators over CRT pacemakers (Adelstein et al., 2017; Leyva et al., 2012 ).
An analysis from the Multicenter Automatic Defibrillator
Implantation Trial with Cardiac Resynchronization Therapy utilized an increase in LVEF percentage points of 14.5% or greater as a metric for CRT super-response (Hsu et al., 2012) . In this heterogeneous population, 25% achieved this level of improvement. Nearly threefourths in our study had an increase in LVEF percentage points of 15 or greater. This wide variation of responses emphasizes the need to perform dedicated studies in specific phenotypes. It is also of note that 10% in our study had no improvement in LVEF. Further research is needed in these subjects who, despite having characteristics favoring good response to CRT, did not derive any benefit.
A higher rate of hypertension among CRT recipients who did not achieve myocardial recovery may indicate the coexistence of hypertensive cardiomyopathy. It has been theorized that hypertensive dilated cardiomyopathy may occur without interval concentric hypertrophy (Garg & Drazner, 2016) . A study in hypertensive patients with normal coronary angiography demonstrated late gadolinium enhancement suggesting microvascular disease and fibrosis (Andersen et al., 2009) . Midwall fibrosis in CRT recipients with NICM has been associated with poor remodeling and clinical outcomes (Leyva et al., 2012) . Subjects in our study who did and did not achieve myocardial recovery had similar systolic blood pressure at the time of CRT
implantation. Yet, we cannot exclude prior damage from a period of unchecked hypertension. Fibrosis quantity and patterns on cardiac magnetic resonance imaging may play a role in differentiating pure LBBB-induced cardiomyopathy from mixed LBBB-induced and hypertensive cardiomyopathy.
The relationship between elevated heart rate and worse prognosis in chronic HF with reduced LVEF has been described (Lechat et al., 2001 ). Reduction in heart rate is one benefit ascribed to beta-blockade (Vukadinović et al., 2017) . Although maximal titration of betablockers is recommended, additional heart rate reduction through inhibition of the I f current by ivabradine results in added risk reduction of HF events (Fiuzat et al., 2016; Swedberg et al., 2010; Yancy et al., 2013) . CRT decreases heart rate within months of implant and may allow higher doses of beta-blockers to be administered due to increases in systolic blood pressure (Biton et al., 2015; Fantoni et al., 2005) . The additional benefit of ivabradine in CRT recipients is unclear given lack of representation in the Systolic Heart failure treatment with the I f inhibitor ivabradine Trial (Swedberg et al., 2010) . 
TA B L E 5 Adverse clinical events by post-CRT LVEF
Ivabradine has been associated with further increase in LVEF in subjects with coronary artery disease, reduced LVEF, and high use of beta-blockers (Ceconi et al., 2011) . Thus, higher heart rate in those who did not have myocardial recovery in our study may represent a target for beta-blocker optimization and I f current inhibition.
Elevated serum BUN concentration is a surrogate marker for renal neurohormonal activation in HF (Testani, Cappola, Brensinger, Shannon, & Kimmel, 2011) . BUN increases are related to complex mechanisms involving increased renin-angiotensin-aldosterone system activity, increased sympathetic nervous system activity, and higher levels of arginine vasopressin (Kazory, 2010) . In patients with reduced LVEF who are hospitalized with decompensated HF, elevated baseline serum BUN is associated with higher postdischarge mortality that may be related to use of high-dose loop diuretics (Filippatos et al., 2007; Testani et al., 2011) . Different combinations of neurohormonal antagonism may have different effects on cardiac remodeling (McKelvie et al.., 2003) . Given the association between loop diuretics and adverse outcomes in those with elevated serum BUN, alternative agents such as vasopressin V2 receptor antagonists, may be more beneficial toward LVEF improvement in select HF patients (Jujo et al., 2016) .
Technological evolution of CRT may lead to even greater recovery rates. The recent development of quadripolar transvenous LV leads has allowed for more pacing vectors. Compared to bipolar leads, quadripolar leads have been associated with decreased risk of death and HF hospitalization (Leyva et al., 2017; Turakhia et al., 2016) . Potential reasons include fewer re-interventions for LV lead migration and premature battery drain from high capture threshold.
Additional vectors may also allow optimization of the QLV interval, which has been associated with improved reverse remodeling (Gold et al., 2011) . Only 22% of our study population had quadripolar leads.
Delivery of current transvenous LV leads is limited by venous
anatomy. Nonresponders may benefit from wireless LV endocardial pacing electrodes that are in development (Reddy et al., 2017) .
Permanent His-bundle pacing is a theoretically attractive option for "true" electrical resynchronization in LBBB-associated NICM (Ajiola, Upadhyay, Macias, Shivkumar, & Tung, 2017; Narula, 1977; Teng, Massoud, & Ajijola, 2016) . It is currently limited by modest rates of successful implantation. A recent multicenter study also reported a 7% rate of late increase in capture threshold that resulted in loss of electrical resynchronization and/or increased battery drain (Sharma et al., 2018) . Long-term data are needed to assess progression of conduction system disease distal to the His-bundle electrode.
Conventional CRT with quadripolar LV leads should be the current preferred system with permanent His-bundle pacing reserved as a bailout strategy for failed or suboptimal transvenous LV lead delivery.
| Study strengths and limitations
The primary strength of the study was rigorous selection of subjects.
A notable feature of the NEOLITH and NEOLITH II studies was the requirement of LBBB at the time of initial diagnosis of NICM (Wang et al., 2016; Wang, Li, et al., 2018) . Subjects with other potential contributing causes to cardiomyopathy were excluded. This increased the likelihood that many had pure LBBB-induced cardiomyopathy (Wang, Adelstein, Singh, Voigt, & Saba, 2018) .
Our study was retrospective and therefore hypothesis-generating. Multicenter prospective studies are needed to confirm our findings. Not all NEOLITH II study subjects had follow-up echocardiograms. Nevertheless, if all 18 subjects excluded for lacking follow-up LVEF measurements were considered nonresponders, myocardial recovery would still have been seen in 46%. Our population was almost entirely of white race/ethnicity. While we only had six African American subjects, they appeared less likely to achieve myocardial recovery. GDMT and CRT programming were not standardized. We did not have uniform time from CRT to follow-up LVEF measurement, yet the median time in both groups was well over F I G U R E 3 Kaplan-Meier curve for probability of survival from all-cause mortality after CRT by myocardial recovery status, or post-CRT LVEF ≥50%. Subjects with myocardial recovery had similar risk for all-cause mortality compared to those without myocardial recovery. CRT: cardiac resynchronization therapy; LVEF: left ventricular ejection fraction 1 year. Therefore, we expect maximum CRT response to have been achieved in both groups. There was no core laboratory for LVEF measurements.
| CON CLUS IONS
In LBBB-associated idiopathic NICM, approximately half achieved myocardial recovery after CRT. These subjects had fewer adverse clinical events when compared to those without the same level of improvement. Myocardial recovery after CRT was associated with absence of hypertension, lower baseline heart rate, and lower serum BUN. These findings suggest a high proportion of those with LBBBassociated idiopathic NICM have pure LBBB-induced cardiomyopathy, provide data to optimize patient care, and identify areas for future research. 
D I SCLOS U R E S
